INT217636

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.20
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
liver 1
fa (Mus musculus)
Pain Link Frequency Relevance Heat
Bioavailability 4 99.00 Very High Very High Very High
Inflammation 42 57.12 Quite High
alcohol 13 39.16 Quite Low
Bile 11 25.52 Quite Low
fibrosis 11 5.00 Very Low Very Low Very Low
agonist 11 5.00 Very Low Very Low Very Low
chemokine 6 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Nicotine 4 5.00 Very Low Very Low Very Low
Inflammatory mediators 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperlipidemia 4 98.82 Very High Very High Very High
Diabetes Mellitus 31 98.44 Very High Very High Very High
Metabolic Syndrome 23 98.24 Very High Very High Very High
Metabolic Disorder 1 97.86 Very High Very High Very High
Fatty Liver 63 96.20 Very High Very High Very High
Nash(non-alcoholic Steatohepatitis) 27 93.96 High High
INFLAMMATION 45 57.12 Quite High
Dyslipidemia /

Combined Dyslipidemia

6 47.28 Quite Low
Insulin Resistance 25 45.04 Quite Low
Hypertension 11 43.20 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Since elevated levels of long chain fatty acids (LCFAs) and LCFA coenzyme A esters (LCFA-CoAs) are observed in hepatic steatosis and several metabolic disorders, including obesity, diabetes and hyperlipidemia, it is of necessity that we understand the mechanism that regulates fatty acid (FA) transport and partitioning of free fatty acids (FFA) and fatty acid-CoA in the initiation of fatty liver lipotoxicity in the progression of NAFLD to NASH.
Regulation (regulates) of FA in liver associated with fatty liver, nash(non-alcoholic steatohepatitis), metabolic disorder, diabetes mellitus, metabolic syndrome and hyperlipidemia
1) Confidence 0.05 Published 2009 Journal PPAR Research Section Body Doc Link PMC2840373 Disease Relevance 1.20 Pain Relevance 0.03
The metabolites of FA and their relative proportions will depend on many factors, including dose, route of administration and animal species.
Regulation (metabolites) of FA
2) Confidence 0.03 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2127228 Disease Relevance 0 Pain Relevance 0
The physiological importance of FA and notably its antioxidant property depends upon its availability for absorption and subsequent interaction with target tissues [12].
Regulation (importance) of FA
3) Confidence 0.02 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2127228 Disease Relevance 0 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox